The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 6.05 is strong.
Ocular Therapeutix has a Altman Z-Score of 6.19, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Ocular Therapeutix's Altman Z-Score or its related term are showing as below:
FRA:0OT'
s Altman Z-Score Range Over the Past 10 Years
Min: -8.89 Med: -0.68 Max: 8.34
Current: 6.05
During the past 13 years, Ocular Therapeutix's highest Altman Z-Score was 8.34. The lowest was -8.89. And the median was -0.68.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Ocular Therapeutix Altman Z-Score Related Terms
Ocular Therapeutix Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0OT vs NKTR, PVLA, GENB: Altman Z-Score Comparison
For the Biotechnology subindustry, Ocular Therapeutix's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Ocular Therapeutix's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8987
+
1.4
*
-1.7005
+
3.3
*
-0.3785
+
0.6
*
14.4452
+
1.0
*
0.0706
=
6.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Ocular Therapeutix (FRA:0OT) has a Altman Z-Score of 6.19 as of Jul. 01, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Ocular Therapeutix and its competitors. According to the industry distribution chart, Ocular Therapeutix ranks #291 out of 929 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Ocular Therapeutix's Altman Z-Score too high?
Ocular Therapeutix's current Altman Z-Score is 6.19. The Biotechnology industry median Altman Z-Score is 2.60. Ocular Therapeutix's value of 6.19 is 138.1% above this industry median. Based on the distribution chart, Ocular Therapeutix ranks #291 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Altman Z-Score compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #291 out of 929 companies for Altman Z-Score. This puts Ocular Therapeutix in the upper half of its industry. The industry median Altman Z-Score is 2.60. Ocular Therapeutix's value of 6.19 is 138.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.60, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Altman Z-Score of 6.19 is 138.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Altman Z-Score is 6.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.84, compared to a current price of €8.55 — trading 122.7% above its estimated fair value. The current Altman Z-Score is 6.19 and 138.1% above the Biotechnology industry median of 2.60. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Altman Z-Score is 6.19 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of €8.55 is trading 122.7% above its estimated GF Value™ of €3.84.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for FRA:0OT:
Altman Z-Score: 6.19
GF Value™: €3.84 vs. price of €8.55 (122.7% above fair value)
Industry Position: 138.1% above the Biotechnology median (#291 of 929)
No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for FRA:0OT
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0OT has been successfully added to your 
